extract
Update: 12 Month Results for Anteris DurAVRTM Transcatheter Heart Valve (THV) Aortic Stenosis First in Human Study
Key Highlights:
1. The DurAVR™ Transcatheter Heart Valve (THV) First-in-Human Study met all performance endpoints with remarkable hemodynamic function sustained to 12 months.
2. DurAVR™ THV demonstrated an outstanding safety profile. All safety endpoints were met: No mortality (all causes), no disabling stroke, no life-threatening bleeding, and no myocardial infarction at 12 months.
3. These encouraging preliminary First-in-Human study results will be further validated in an FDA-approved Early Feasibility Study (EFS) in early 2023.
extract Update: 12 Month Results for Anteris DurAVRTM...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.15 |
Change
-0.500(3.19%) |
Mkt cap ! $291.2M | |||
| Open | High | Low | Value | Volume |
| $15.75 | $15.75 | $15.00 | $294.3K | 19.33K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1135 | $15.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.35 | 88 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |